BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9874186)

  • 1. Ependymomas: MIB-1 proliferation index and survival.
    Ritter AM; Hess KR; McLendon RE; Langford LA
    J Neurooncol; 1998 Oct; 40(1):51-7. PubMed ID: 9874186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry.
    Prayson RA
    Ann Diagn Pathol; 1999 Feb; 3(1):11-8. PubMed ID: 9990108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases.
    Prayson RA
    Am J Clin Pathol; 1998 Nov; 110(5):629-34. PubMed ID: 9802348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
    Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
    Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis.
    Verstegen MJ; Leenstra DT; Ijlst-Keizers H; Bosch DA
    J Neurooncol; 2002 Jan; 56(1):21-8. PubMed ID: 11949823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
    Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
    Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
    Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
    Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma.
    Ho DM; Hsu CY; Wong TT; Chiang H
    J Neurooncol; 2001 Aug; 54(1):77-85. PubMed ID: 11763426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity.
    Prayson RA
    Mod Pathol; 1997 Apr; 10(4):304-10. PubMed ID: 9110291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
    Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
    Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas.
    Rushing EJ; Yashima K; Brown DF; White CL; Shay JW; Risser RC; Gazdar AF
    J Neuropathol Exp Neurol; 1997 Oct; 56(10):1142-6. PubMed ID: 9329458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular proliferation in pilocytic and diffuse astrocytomas.
    Giannini C; Scheithauer BW; Burger PC; Christensen MR; Wollan PC; Sebo TJ; Forsyth PA; Hayostek CJ
    J Neuropathol Exp Neurol; 1999 Jan; 58(1):46-53. PubMed ID: 10068313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma.
    Wolfsberger S; Fischer I; Höftberger R; Birner P; Slavc I; Dieckmann K; Czech T; Budka H; Hainfellner J
    Am J Surg Pathol; 2004 Jul; 28(7):914-20. PubMed ID: 15223962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central neurocytoma: histologic atypia, proliferation potential, and clinical outcome.
    Mackenzie IR
    Cancer; 1999 Apr; 85(7):1606-10. PubMed ID: 10193953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
    Abramovich CM; Prayson RA
    Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index.
    Schröder R; Ploner C; Ernestus RI
    Neurosurg Rev; 1993; 16(2):145-50. PubMed ID: 8345908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in intracranial ependymomas in children.
    Figarella-Branger D; Civatte M; Bouvier-Labit C; Gouvernet J; Gambarelli D; Gentet JC; Lena G; Choux M; Pellissier JF
    J Neurosurg; 2000 Oct; 93(4):605-13. PubMed ID: 11014538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
    Pollack IF; Hamilton RL; Burnham J; Holmes EJ; Finkelstein SD; Sposto R; Yates AJ; Boyett JM; Finlay JL
    Neurosurgery; 2002 Jun; 50(6):1238-44; discussion 1244-5. PubMed ID: 12015841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subependymomas: clinicopathologic study of 14 tumors, including comparative MIB-1 immunohistochemical analysis with other ependymal neoplasms.
    Prayson RA; Suh JH
    Arch Pathol Lab Med; 1999 Apr; 123(4):306-9. PubMed ID: 10320142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases.
    Machen SK; Prayson RA
    Hum Pathol; 1998 Dec; 29(12):1511-6. PubMed ID: 9865840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.